CWM
VRTX icon

Centurion Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Centurion Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-561
Closed -$251K – 324
2026
Q1 		$251K Sell
561
-42
-7% -$19.6K 0.06% 266
2025
Q4 		$273K Buy
603
+18
+3% +$7.76K 0.06% 250
2025
Q3 		$229K Buy
585
+84
+17% +$35.1K 0.05% 263
2025
Q2 		$223K Buy
+501
New +$231K 0.06% 213

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return

Centurion Wealth Management's VRTX Position: Q2 2026 in Review

Centurion Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 561 shares — an estimated $251K sold.

Centurion Wealth Management first reported a position in VRTX in Q2 2025 and held it in 4 quarters. The position peaked at $273K in Q4 2025. 252 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Centurion Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Centurion Wealth Management sold 561 Vertex Pharmaceuticals shares in Q2 2026, an estimated $251K.
  • Centurion Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Centurion Wealth Management's Vertex Pharmaceuticals position peaked at $273K in Q4 2025.
  • 252 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Centurion Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.